Glu-plasminogen, the native form of plasminogen, interacts in a specific and saturable manner with unstimulated human platelets, and the binding is enhanced fivefold by thrombin stimulation (Miles and Plow, 1985. J. Biol. Chem. 260:4303). This study characterizes the nature of the Glu-plasminogen binding sites by analyzing platelets deficient in selected proteins and functions. Platelets from patients with afibrinogenemia, Gray platelet syndrome, and the Cam Variant of thrombasthenia, a form of thrombasthenia with near normal levels of glycoprotein HIb/IIIa (GPIIb/IIIa), showed minimal augmentation of plasminogen binding to thrombin-stimulated platelets but normal binding to unstimulated platelets. This selective deficiency indicates that two distinct mechanisms are involved in the interaction of plasminogen with platelets. These abnormal platelets share a deficiency in fibrinogen. Surface expression of platelet fibrinogen, however, was not sufficient for enhanced plasminogen binding to stimulated platelets, and experiments with alpha-thrombin and gamma-thrombin indicated that fibrin formation on the platelet surface is necessary for the augmented plasminogen binding. Unstimulated and stimulated thrombasthenic platelets deficient in GPIIb/IIIa bound markedly reduced levels of plasminogen, which suggests a role for GPIIb/IIIa in plasminogen binding to unstimulated platelets. Treatment of platelets to dissociate the heterodimeric complex of GPIIb/IIIa did not significantly perturb plasminogen binding to unstimulated platelets, but the complex may be necessary for thrombin-stimulated plasminogen binding via its interaction with platelet fibrin.
Introduction
Platelets possess both pro-fibrinolytic and anti-fibrinolytic activities (1, 2) , and the proximal relationship between platelets and fibrin within thrombi suggests that these activities may contribute to the regulation of fibrinolysis. Interaction of plasminogen with platelets provides one mechanism by which platelets might participate in fibrinolysis. Early evidence in the literature suggested this possibility (1, 3) . We have recently demonstrated specific and saturable binding of plasminogen to platelets (4) . This interaction occurred with high capacity: at saturation, resting and thrombin stimulated platelets bound 37,000±10,000 and 190,000±45,000 plasminogen molecules/cell, respectively.
The apparent dissociation constants (Kd) for the interaction of Portions of this work were presented at the Xth International Congress on Thrombosis and Haemostasis, San Diego, CA, July, 1985. Receivedfor publication 20 August 1985 and in revisedform 15 January 1986. plasminogen with resting and thrombin-stimulated platelets were similar (1.9-2.6 ,uM). Thus, it was not possible to determine whether the enhanced plasminogen binding observed after platelet stimulation reflected an extension of the same binding mechanism observed on resting cells or involved an independent one.
The high binding capacity of platelets for plasminogen re- stricts the candidate binding sites to only major platelet constituents. For example, platelets contain alpha2-antiplasmin and histidine-rich glycoprotein, which are known to bind plasminogen (5) (6) (7) , but the concentrations ofthese proteins (530 [8] and 3,700 [9] molecules/platelet, respectively) are too low to account readily for the capacity of platelets for plasminogen. Of the platelet surface membrane proteins, GPIb at 26,000±10,000 copies per platelet (10) and glycoprotein IIb/IIIa (GPIIb/IIIa) at 40,000-50,000 copies per platelet (1 1, 12) are potential candidates for plasminogen binding sites on resting platelets. Since agonists alter the function of both of these membrane proteins as evidenced by ristocetin-supported binding of von Willebrand Factor to GPIb (10, 13) and the role of GPIIb/IIIa in thrombinstimulated binding of fibrinogen (12, (14) (15) (16) , fibronectin (17) , and von Willebrand Factor (18) , their alteration may also contribute to the increase in plasminogen binding to stimulated platelets. Thrombin stimulation also results in the expression of new species on the surface ofactivated platelets. Fibrinogen and thrombospondin are major platelet alpha granule constituents that become expressed on the surface ofstimulated platelets ( 19, 20) . Thrombospondin binds plasminogen with high affinity (21) . Fibrin, which may be formed on the platelet surface as a result of the proteolytic action of thrombin on released platelet fibrinogen, binds Glu-plasminogen with considerably greater affinity than does fibrinogen (22) . Thrombospondin at 99,000 trimeric subunits/platelet (23) and fibrinogen at 126,000 molecules/ platelet (24) are present at sufficient concentrations to contribute to plasminogen binding to the stimulated cells.
In this study, we have used various conditions ofstimulation and membrane perturbation and platelets congenitally deficient in surface glycoproteins and/or internal pools ofproteins to assess possible contributions of specific platelet proteins to the interaction of plasminogen with stimulated and unstimulated platelets. Our results show that distinct mechanisms are involved in the binding of plasminogen to unstimulated and thrombinstimulated platelets. Moreover, platelet molecules that may directly mediate or participate in the binding of plasminogen are identified.
Methods
Plasminogen. Glu-plasminogen was isolated from fresh frozen human plasma by affinity chromatography on lysine-Sepharose (25) in the presence of 1 mM benzamidine, 0.02% NaN3, and 0.003 M EDTA, followed by molecular exclusion chromatography on Ultrogel AcA44 (26). The plasminogen was .95% pure as assessed by Coomassie Blue staining of as previously described (4) . Plasminogen concentrations were determined spectrophotometrically at 280 nm using the extinction coefficient of 16.8 (27) , and the absence of Lys-plasminogen in the Glu-plasminogen preparations was established by amino-terminal analyses (28) . Plasminogen was labeled by a modified chloramine-T procedure as previously described (29) . Specific activities of the '25I-plasminogen preparations used during the course of these studies were 0.6±0.2 ACi/Ag, and the precipitability ofthe radioactivity in 13% trichloroacetic acid was .95%. As previously reported from our laboratory (4) and verified with each preparation used in the present study, when the '25I-plasminogen preparations were run on 10% polyacrylamide gels in the presence of SDS under either reducing or nonreducing conditions .90% of the applied radioactivity migrated as a single peak with the same mobility as unlabeled plasminogen. In addition, when analyzed by slicing and counting alkali gels under nondenaturing conditions, the '25I-plasminogen preparation migrated as a single band with a similar mobility to the single band observed on stained gels with unlabeled plasminogen.
Anti-fibrinogen F(ab92 fragments. Antibodies to human fibrinogen were raised by biweekly injections of human fibrinogen in complete Freund's adjuvant into goats. To prepare F(ab')2 fragments, we precipitated the antiserum with ammonium sulfate at 35% saturation. The precipitate was dissolved in H20, and dialyzed into 0.12 M Na acetate, pH 3.8, 0.05 M NaCl, 0.1% NaN3. This material was then digested with 3 mg pepsin/100 mg protein for 18 h at 37°C, dialyzed into 0.01 M Na phosphate, 0.15 M NaCl, pH 7.3 and immunopurified on a column of fibrinogen-Sepharose. Bound F(ab')2 fragments were eluted with 0.1 M glycine HCl, pH 2.2, 10-4 M phenylmethylsulfonyl fluoride (PMSF),' 0.02% NaN3, neutralized with NaOH to pH 7.0, dialyzed into phosphatebuffered saline (PBS), and radioiodinated by a modified chloramine T procedure (30) to specific activities of 1.4±0.8 uCi/Ag. The '231-labeled F(ab')2 preparations and extracts of platelets with bound antibody fragments were analyzed on polyacrylamide gels in the presence of SDS. Based upon densitometric scans of the autoradiographs of these gels, only 12% intact IgG was detected in the starting preparation and 7% in the platelet bound material.
Radioimmunoassays (RIAs). Plasma and platelet fibrinogen were quantitated in a double antibody RIA as previously described (30). Platelets (5 X 108) were lysed in 0.5 ml of 0.5% Triton X 100, 5 mM EDTA, and 1 mM PMSF. The fibrinogen content of these lysates was determined relative to a standard of purified plasma fibrinogen diluted into the Triton mixture. Fibrinopeptide A release was also determined in a double-antibody RIA. Supernatants derived from stimulated platelets were precipitated with an equal volume of 60% ethanol, 0.625% human IgG, I mM PMSF, and 5 mM EDTA (31) before analyses. Platelet thrombospondin was quantitated by RIA of cell lysates as previously described (23) .
Platelet isolation and binding assays. Human blood donated by healthy volunteers was collected into acid-citrate-dextrose, and platelets were isolated by differential centrifugation followed by gel filtration on Sepharose 2B in divalent ion free Tyrode's buffer, pH 7.2, containing 20 mg/ml bovine serum albumin (BSA) (32 were calculated from the specific activity of the radiolabeled plasminogen using a molecular weight of 90,000. We have reported previously that 108 platelets contain 21 ng plasminogen (4) . Therefore, in binding assays using 20.1 MuM 1251-plasminogen, if fully released, platelet plasminogen would occupy <0.01% of the binding sites on the cells and would not appreciably change the specific activity of the ligand. In experiments with abnormal platelets in which apparent dissociation constants and the number of binding sites for plasminogen were determined, varying concentrations of unlabeled plasminogen were added to the platelets with a constant amount (0.1-0.2 MM) of '25I-plasminogen. As a relatively low affinity system, it was not feasible to add sufficient unlabeled plasminogen to ensure that all residual radioactivity bound at high concentrations of unlabeled plasminogen represented nonspecific binding. Therefore, nonspecific binding was treated as a fitted parameter in the ligand computer program of Munson and Rodbard (33) as modified by Shih. As previously published (4), this analysis provided estimates for the nonspecific binding of the ligand to thrombin-stimulated and resting platelets of 0. 14 and 0.17% of total added ligand. These values were used to calculate nonspecific binding at input concentrations of plasminogen utilized in the present study. Accordingly, at a 0.1 MM input concentration of '251-plasminogen, 12% of the total binding to thrombin-stimulated platelets and 25% of the binding to unstimulated platelets was calculated to be nonspecific. At the highest concentrations of unlabeled plasminogen added (10-30 MM), the residual amount of radioactivity associated with stimulated and unstimulated platelets during the course of these studies was 14.2 and 25.9%, indicating the validity of the estimates for nonspecific binding. Since nonspecific binding was relatively low at 0.1-0.2MuM added plasminogen, this concentration was utilized in experiments in which a single dose of ligand was added.
Binding of radiolabeled anti-fibrinogen F(ab')2 fragments was measured in a similar way with an input radiolabeled ligand concentration of 4.4 X 10-8 M, determined to be a saturating concentration. '251-Fibrinogen binding to platelets was measured as previously described (32) .
Abnormal platelets. The Gray platelets (24) , Bernard Soulier platelets (10, 34) , afibrinogenemic platelets (35), thrombasthenic platelets (36) , and Cam Variant thrombasthenic platelets (37) used in this study have been previously characterized. The thrombasthenic platelets had reduced fibrinogen, .10% GPIIb/IIIa content as determined by monoclonal antibody binding and very low fibrinogen receptor expression in response to ADP. As previously reported (37) , and detailed in a submitted manuscript (Ginsberg, M. H., A. Lightsey, T. J. Kunicki, A. Kaufman, G. Marguerie, and E. F. Plow, manuscript submitted for publication), Cam Variant platelets also have reduced platelet fibrinogen levels (.3% of normal), markedly reduced ADP-induced fibrinogen receptor expression, fail to aggregate in response to ADP or thrombin, and have near-normal levels of GPIIb/IIIa accessible to lactoperoxidase-catalyzed surface radioiodination. The Gray platelets have reduced contents of alpha granule proteins including fibrinogen, thrombospondin, platelet factor 4 (PF4), and platelet-derived growth factor (24) . The only defect observed in the afibrinogenemic platelets used in this study is decreased platelet fibrinogen content, and these platelets have been shown to aggregate and bind fibrinogen normally when provided with extracellular fibrinogen (35). The Bernard-Soulier platelets have reduced levels ofGPIb and do not aggregate or bind von Willebrand Factor in response to ristocetin (10, 34) . The Gray, Bernard-Soulier, and thrombasthenic platelets and their normal control platelets, drawn in parallel, required overnight shipping before isolation. In some cases, the extent of plasminogen binding of the normal platelets shipped in parallel was reduced compared to freshly isolated, normal platelets. For example, the control platelets shipped with the thrombasthenic platelets bound 400-1,800 plasminogen molecules/ platelet at an input 1251-plasminogen concentration of0.2 MM compared with 3,700+1,050 molecules per cell for freshly isolated platelets (4).
Thrombin stimulation of the shipped platelets, however, still resulted in a three-to fivefold enhancement in plasminogen binding. Therefore, binding data from these experiments were expressed as a percent of the binding to the control platelets.
Reagents. Fibrinogen was isolated (38) and radiolabeled as previously described (32 
Results
Role ofplatelet fibrinogen in plasminogen binding. Expression of platelet fibrinogen on the cell surface is a consequence of platelet stimulation (41) and fibrinogen is present at sufficient concentrations in platelets (24) to account for plasminogen binding on a stoichiometric basis. Therefore, the role of platelet fibrinogen in plasminogen binding was assessed by examining '251-plasminogen binding to platelets congenitally deficient in intracellular fibrinogen. At the time ofthis analysis, the patient's plasma and platelet fibrinogen levels were 0.35 and 4.6% of the normal control, respectively. Maintaining the '25I-plasminogen at a 0.2-MM concentration, varying concentrations of unlabeled plasminogen ranging from 0.7 MM to 9.4 AuM were added to the normal and afibrinogenemic platelets. The specific binding isotherms derived from the dose-dependent inhibition of 1251-plasminogen binding by unlabeled plasminogen for the unstimulated afibrinogenemic and control normal platelets drawn in parallel are shown in Fig. 1 A. Under this condition, the binding curves were very similar. When these data were analyzed in Scatchard plots, 32,800 molecules were bound per cell and 50% saturation of the binding sites was achieved at 1.25 ,uM plasminogen for the unstimulated afibrinogenemic platelets while control platelets bound 28,000 molecules/cell with 50% saturation occurring at 2.3 MM plasminogen. These values are very similar to the binding parameters previously determined (4) for unstimulated platelets: dissociation constant (Kd) = 1.9±0.2 MM and 37,000±10,500 plasminogen molecules bound per cell. Thus, plasminogen binding to unstimulated platelets appears to occur independently of the platelet content of fibrinogen. In contrast, plasminogen binding obtained with the thrombin-stimulated afibrinogenemic and normal platelets differed significantly. When 0.2 AM 12511 plasminogen was added, the afibrinogenemic platelets bound 10,700 molecules/platelet, whereas 35,300 molecules bound to the normal control platelets prepared in parallel. The binding isotherms for plasminogen binding to thrombin-stimulated afibrinogenemic and normal platelets are shown in Fig. 1 Fig. 1 B. As shown, at the 9.6-MuM plasminogen input concentration, the number of additional plasminogen molecules bound to the normal and afibrinogenemic platelets are calculated to be 101,000 and 20,800, respectively, a 4.9-fold difference.
As only one afibrinogenemic patient was available for study, Gray platelets that are deficient in alpha-granule proteins including fibrinogen were used to corroborate these results. The Gray platelets also showed selective reduction in thrombinstimulated plasminogen binding. At Of the platelet agonists, thrombin is unique in its capacity to convert fibrinogen to fibrin. To assess the role of fibrin formation in augmented plasminogen binding, the effects of gamma-thrombin, a proteolytic derivative of alpha-thrombin which has reduced fibrin converting activity relative to its platelet stimulatory effects (42) , was compared with alpha-thrombin on '251I-plasminogen binding. The release of fibrinopeptide A from platelets stimulated with alpha-thrombin and gamma-thrombin was measured to monitor the extent of fibrin formation. As shown in Table II , both alpha-thrombin and gamma-thrombin increased '251-plasminogen binding to platelets in a dose-dependent manner. With both thrombin forms, enhanced plasminogen binding was observed at concentrations of the stimuli which induced detectable fibrinopeptide A release. At low doses of alpha-thrombin and gamma-thrombin, the extent of 125I-plasminogen binding was similar to that observed with unstimulated platelets, and no fibrinopeptide A release was detected. At doses exceeding 5 mU/ml alpha-thrombin and 88 mU/ml gammathrombin, 125I-plasminogen binding was augmented and fibrinopeptide A release was detected.
Role ofplatelet membrane proteins in plasminogen binding. to explore the role ofthe major membrane glycoprotein, GPIIb/ Illa, in plasminogen binding, the interaction of the ligand with thrombasthenic platelets was evaluated. Platelets from two thrombasthenic patients were utilized. The platelets from these patients have been previously characterized as having reduced levels of GPIIb/IIIa (36) as well as having a deficit in fibrinogen receptor expression and in intracellular fibrinogen (43). From the studies described above, a reduction in thrombin-stimulated binding of plasminogen to these platelets is anticipated due to Plasminogen binding to thrombin-stimulated and unstimulated platelets from one of these patients has been analyzed in Fig. 3 . Unstimulated platelets from this patient bound plasminogen in a very similar fashion to normal control platelets (Fig. 3 A) . For example, at a 8 MM plasminogen concentration, the platelets of the patient bound 35,500 molecules/platelet compared with 33,000 molecules to the normal platelets. Thrombin-stimulated binding of plasminogen to the patient's platelets was, however, reduced (Fig. 3 B) and this was also observed for another affected min. In B, the platelets are unstimulated; 2.5 mM theophylline and 9 MM PGE, were substituted for the thrombin, and platelets were used at a concentration of 1 X 108 ml. Unstimulated control platelets bound 8,100 molecules per cell at saturation, and binding was enhanced 3.2-fold in the presence of thrombin. family member whose platelets were tested. When molecules bound per unstimulated cell were subtracted from total binding at each plasminogen concentration, thrombin-induced binding was only observed at the two highest input plasminogen concentrations tested and was only 17% ofthe normal control. Thus, the extent of the defect in thrombin-stimulated plasminogen binding to platelets in these patients was more pronounced than for the afibrinogenemic cells, perhaps due to the double deficiency in platelet fibrinogen as well as its receptor.
To establish that abnormalities ofplatelet membrane proteins do not generally perturb plasminogen binding, the interaction ofplasminogen with platelets from a patient with Bernard-Soulier syndrome was investigated. Platelets from patients with BernardSoulier syndrome lack GPIb (44). In addition, recent studies have suggested that these platelets may also be deficient in GPV and a 20,000 mol wt component (45) . As shown in Table III , both unstimulated and thrombin stimulated Bernard-Soulier platelets bound plasminogen. Compared with the normal platelets analyzed in parallel, the Bernard-Soulier platelets bound approximately twofold more plasminogen under both stimulated and nonstimulated conditions, which may reflect the larger size of these platelets (34, 44) . This finding is consistent with a published report showing a twofold enhancement in 1251I-von Willebrand Factor binding to thrombin-stimulated Bernard-Soulier platelets compared with control platelets (18) . Thus, platelets that are deficient in major membrane proteins are capable of binding plasminogen, which indicates that the deficit in plasminogen binding observed with the thrombasthenic platelets is unique to this syndrome.
The membrane glycoprotein, GPIIb/IIIa, exists as a calciumdependent heterodimer (46) in both unstimulated and stimulated platelets (11, 12, 39, (46) (47) (48) (49) (50) (51) . Calcium chelation at 37°C but not 22°C has been shown to disrupt the heterodimer on the cell (47) (48) (49) (50) . Therefore, the effect of calcium chelation at these two temperatures on the interaction of plasminogen with platelets was examined (Table IV) . Monoclonal antibody AP-2 reacts with the GPIIb/IIIa complex in the presence of calcium but not with GPIIb or GPIIIa in the presence of calcium or EDTA (39, 40) . Using radioiodinated AP-2, we established that calcium chelation with EDTA or Mg-EGTA at 37°C reduced expression of the AP-2 epitope on our stimulated and nonstimulated platelet preparations by >90% and reduced the epitope by <10% at 22°C. Calcium chelation at 37°C had a differential effect on plasminogen binding to thrombin-stimulated and unstimulated platelets. Thrombin-stimulated binding was markedly reduced (.83% inhibition). In contrast, treated, unstimulated platelets at 37°C retained their capacity to bind plasminogen. In the experiment shown in Table IV , Mg-EGTA caused a 10% inhibition of plasminogen binding to the unstimulated platelets. In five similar experiments, the mean extent ofinhibition under this condition was 26±19%. The inhibition observed in the presence of EDTA was 12±14% (10 experiments 
Discussion
We have previously shown that Glu-plasminogen binds specifically to resting platelets and that thrombin stimulation of the cells augments the extent of the interaction by approximately fibrin. The differential effects ofcalcium chelation at 37°C on plasminogen binding to thrombin-stimulated and unstimulated platelets-marked inhibition of stimulated binding as contrasted with minimal inhibition of unstimulated binding-further support the existence of two distinct mechanisms of plasminogen binding to platelets. The marked reduction in plasminogen binding to unstimulated thrombasthenic platelets suggests that GPIIb/IIIa is required for this interaction. The intact heterodimeric form of GPIIb/IIIa does not appear to be necessary for this interaction since plasminogen did bind to unstimulated platelets under conditions (at 37°C in the absence of calcium) which dissociate the complex (46-49) and destroy the epitope recognized by AP-2. Thus, the GPIlb or GPIIIa subunits may be sufficient to support unstimulated plasminogen binding. Aggregation of dissociated GPIIb and GPIIIa has been reported (47, 50) , and this may explain the greater variability in plasminogen binding under dissociating conditions observed with unstimulated platelets (see Table IV ). Under conditions which cause complex dissociation (at 37°C in the presence of EDTA), a marked reduction in both thrombin-stimulated plasminogen binding and fibrin(ogen) surface expression was observed. Thus, via its interaction with fibrinogen, the GPIIb/IIIa complex may also participate in plasminogen binding to thrombin-stimulated platelets. At was not reduced, which suggests that a major platelet substrate of plasmin cleavage, GPIb, (54) does not serve as a primary plasminogen binding site as previously suggested (55) .
It has been estimated with monoclonal antibodies that platelets express 40,000-50,000 GPIIb/IIIa molecules on their surfaces (1 1, 12 ). This level readily accommodates the binding of plasminogen to unstimulated platelets, 37,000±10,000 molecules maximally bound, at a 1:1 stoichiometry. The similarity in the extent of plasminogen binding to unstimulated cells and thrombin stimulated afibrinogenemic and Gray platelets suggests that the constitutive binding sites on unstimulated platelets remain available on stimulated cells. Therefore, of the total 190,000 binding sites on thrombin stimulated platelets, -150,000 new sites are expressed per platelet. In the absence of platelets, plasminogen binds to fibrin with a 2:1 stoichiometry (22) . Therefore, only 50% of the -126,000 platelet fibrinogen molecules would need to become cell-surface associated in order to account for the extent of plasminogen binding to thrombin stimulated platelets. This level is greater than would be predicted if surface expression simply involved secretion and binding of platelet fibrinogen to its cell surface receptor as platelet and plasma fibrinogen bind to platelets with the same affinity (56). However, surface expression of adhesive proteins (57) including fibrinogen (41) may occur by a mechanism independent of their release and rebinding and could account for sufficient association of fibrin with the platelet to support stoichiometric binding ofplasminogen. The dissociation constant of Glu-plasminogen, the ligand used in the study, for fibrin in the absence of platelets has been estimated to be 38 AM (22) . As previously reported (4) and confirmed during the course of this study, the apparent dissociation constant ofplasminogen for thrombin stimulated as well as unstimulated platelets is 1-6 MM. Either the platelet surface enhances the apparent affinity of fibrin for plasminogen or the binding assay utilized has a systematic effect upon the estimation of the affinity of this interaction. Studies with various plasminogen derivatives are presently in progress and should resolve these possibilities.
Our previous data support the suggestion that platelets have the potential to enhance fibrinolysis by localizing plasminogen in a thrombus and enhancing its activation (4) . The studies re-ported here indicate that the GPIIb/IIIa molecule and platelet fibrin(ogen) may play dual roles in clot formation and dissolution. Initially, these molecules are required for platelet aggregation and thrombus formation. In addition, these molecules are also required for plasminogen binding which may ultimately promote clot dissolution.
